Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2)

por Punt, C. J., Henzen-Logmans, S. C., Bolhuis, R. L., Stoter, G.
Publicado em 1990

Regarding: ‘Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array’

por Pander, J, Gelderblom, H, van der Straaten, T, Punt, C J A, Guchelaar, H-J
Publicado em 2010

Tallimustine in advanced previously untreated colorectal cancer, a phase II study.

por Punt, C. J., Humblet, Y., Roca, E., Dirix, L. Y., Wainstein, R., Polli, A., Corradino, I.
Publicado em 1996

Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma

por Kamm, Y J L, Peters, G J, Hull, W E, Punt, C J A, Heerschap, A
Publicado em 2003

UGT1A1(*)28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study

por Kweekel, D M, Gelderblom, H, Van der Straaten, T, Antonini, N F, Punt, C J A, Guchelaar, H-J
Publicado em 2008

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.

por Punt, C. J., van Herpen, C. M., Jansen, R. L., Vreugdenhil, G., Muller, E. W., de Mulder, P. H.
Publicado em 1997

Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood

por Vries, T J de, Fourkour, A, Punt, C J A, Diepstra, H, Ruiter, D J, Muijen, G N P van
Publicado em 1999

Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array

por Kweekel, D M, Antonini, N F, Nortier, J W R, Punt, C J A, Gelderblom, H, Guchelaar, H-J
Publicado em 2009

Dendritic cell vaccination and immune monitoring

por Aarntzen, E. H. J. G., Figdor, C. G., Adema, G. J., Punt, C. J. A., de Vries, I. J. M.
Publicado em 2008

Ethnic differences in colon cancer care in the Netherlands: a nationwide registry-based study

por Lamkaddem, M., Elferink, M. A. G., Seeleman, M. C., Dekker, E., Punt, C. J. A., Visser, O., Essink-Bot, M. L.
Publicado no BMC Cancer (2017)

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

por Goey, S. H., Eggermont, A. M., Punt, C. J., Slingerland, R., Gratama, J. W., Oosterom, R., Oskam, R., Bolhuis, R. L., Stoter, G.
Publicado em 1995

Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases

por Mekenkamp, L J M, Koopman, M, Teerenstra, S, van Krieken, J H J M, Mol, L, Nagtegaal, I D, Punt, C J A
Publicado em 2010

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

por Kruit, W. H., Punt, C. J., Goey, S. H., de Mulder, P. H., Gratama, J. W., Eggermont, A. M., Bolhuis, R. L., Stoter, G.
Publicado em 1996

Mitochondrial microsatellite instability in patients with metastatic colorectal cancer

por Venderbosch, S., van Vliet, S., Craenmehr, M. H. C., Simmer, F., de Haan, A. F. J., Punt, C. J. A., Koopman, M., Nagtegaal, I. D.
Publicado no Virchows Arch (2015)

GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group

por Kweekel, D M, Koopman, M, Antonini, N F, Van der Straaten, T, Nortier, J W R, Gelderblom, H, Punt, C J A, Guchelaar, H-J
Publicado em 2008

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

por Punt, C. J., Voest, E. E., Tueni, E., Van Oosterom, A. T., Backx, A., De Mulder, P. H., Hecquet, B., Lucas, C., Gerard, B., Bleiberg, H.
Publicado em 1997

Assessment of Blood Hemodynamics by USPIO-Induced R(1) Changes in MRI of Murine Colon Carcinoma

por Gambarota, Giulio, van Laarhoven, H. W. M., Philippens, M., Peeters, W. J. M., Rijken, P., van der Kogel, A., Punt, C. J. A., Heerschap, A.
Publicado em 2010

Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review

por Sloothaak, D A M, Mirck, B, Punt, C J A, Bemelman, W A, van der Bilt, J D W, D'Hoore, A, Tanis, P J
Publicado no Br J Cancer (2014)

Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonam...

por van Kesteren, Charlotte, Mathôt, R A A, Raymond, E, Armand, J P, Fumoleau, P, Punt, C, Ravic, M, Wanders, J, Beijnen, J H, Schellens, J H M
Publicado em 2002

Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule

por Awada, A, Punt, C J A, Piccart, M J, Tellingen, O Van, Manen, L Van, Kerger, J, Groot, Y, Wanders, J, Verweij, J, Wagener, D J Th
Publicado em 1999